Outlook Therapeutics, Inc.

OTLK Nasdaq SEC CIK 1649989
Follow Outlook Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$20.3M −0.8% vs same quarter last year
EPS, diluted −$0.15 +72.7% vs same quarter last year
Operating cash flow −$21M −76.5% vs same quarter last year
Operating income −$10.8M +31.4% vs same quarter last year
Net income by quarter
$5.7M
$17.4M
−$46.4M
−$20.2M
−$13.3M
−$23.1M
−$4.5M
−$20.3M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income12 fiscal years
  • Revenue
  • Net income
−$100M−$75M−$50M−$25M$0$25MFY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$1.4M−$62.4M
FY24-−$75.4M
FY23-−$59M
FY22-−$66.1M
FY21-−$53.2M
FY20-−$35.2M
FY19$8.1M−$34.5M
FY18$3.1M−$30.1M
FY17$3.8M−$38.8M
FY16$3M−$53.3M
FY15$5.2M−$47.4M
FY14--
MarginsShare of revenue
  • Operating margin
  • Net margin
−6000%−4000%−2000%0%FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−4744.3%−4416.2%
FY24--
FY23--
FY22--
FY21--
FY20--
FY19−445.6%−423.8%
FY18−960.1%−974.6%
FY17−941.4%−1019.3%
FY16−1723.3%−1788.9%
FY15−892.1%−908.1%
FY14--
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22-
FY21-
FY20-
FY19−$32.7M
FY18−$35.8M
FY17−$15.8M
FY16−$46.6M
FY15−$36.3M
FY14-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Outlook Therapeutics
  • Healthcare median
−6000%−4000%−2000%0%FY15FY17FY19FY21FY23FY25
Show the numbers
YearOutlook TherapeuticsHealthcare median
FY25−4416.2%−30.6%
FY24-−47%
FY23-−58%
FY22-−80.4%
FY21-−71.9%
FY20-−62.2%
FY19−423.8%−46.3%
FY18−974.6%−49.6%
FY17−1019.3%−45.9%
FY16−1788.9%−36%
FY15−908.1%−38.4%
FY14-−35.5%